 WILMETTE, Ill., Feb. 11, 2021 GLOBE NEWSWIRE -- Monopar Therapeutics Inc. Nasdaq: MNPR, a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the publication of a peer-reviewed study in the European Journal of Cancer which shows the potential utility of MNPR-101 as a uPAR imaging agent to improve surgical outcomes in bladder cancer. 